We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
HEMLIBRA (Roche Products Pty Limited)
Product name
HEMLIBRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
104 working days (255)
Active ingredients
emicizumab (rch)
Registration type
NCE/NBE
Indication
HEMLIBRA is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.